Holen Sie sich die Stockscreener-App
0.9997
7.44%
-0.0803
Handel nachbörslich:
1.01
0.0103
+1.03%
Schlusskurs vom Vortag:
$1.08
Offen:
$1.11
24-Stunden-Volumen:
584.65K
Relative Volume:
0.39
Marktkapitalisierung:
$5.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.27M
KGV:
-0.0467
EPS:
-21.4132
Netto-Cashflow:
$-9.40M
1W Leistung:
-25.95%
1M Leistung:
-12.31%
6M Leistung:
-34.66%
1J Leistung:
-84.02%
1-Tages-Spanne:
$0.9992
$1.1301
1-Wochen-Bereich:
$0.9992
$2.37
52-Wochen-Spanne:
$0.9992
$6.666
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Firmenname
Dermata Therapeutics Inc
Sektor
Branche
Telefon
(858)-223-0882
Adresse
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Vergleichen Sie DRMA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
0.9997 | 5.43M | 0 | -11.27M | -9.40M | -21.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.36B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.95B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.13B | 3.81B | -644.79M | -669.77M | -6.24 |
Dermata Therapeutics Inc Aktie (DRMA) Neueste Nachrichten
Dermata Therapeutics stock hits 52-week low at $1 - Investing.com
Dermata (DRMA) Initiates Warrant Exercise to Raise $6.2 Million - GuruFocus
Biotech Stock Dermata Therapeutics, Inc. (Nasdaq: DRMA) Makes NASDAQ Top Gainer List on Positive Phase 3 Results - Investorideas.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Dermata Therapeutics (NASDAQ:DRMA) Shares Up 5.2% – Here’s What Happened - Defense World
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules - Yahoo Finance
Dermata Raises Fresh $6.2M Capital: New Funding Fuels Clinical Pipeline Advancement - Stock Titan
Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Benzinga
Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne - Benzinga
Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall - Benzinga
Pre-Market Momentum: Dermata Therapeutics (DRMA) Sees Sharp Gains - Stocks Telegraph
XYNGARI shows promise in Phase 3 acne trial By Investing.com - Investing.com South Africa
Dermata shares rise on positive acne treatment trial results By Investing.com - Investing.com South Africa
Dermata's XYNGARI(TM) Phase 3 Trial Topline Data Meets All Primary Endpoints - MarketScreener
XYNGARI shows promise in Phase 3 acne trial - Investing.com
First-Ever Weekly Acne Treatment XYNGARI Achieves Breakthrough in Phase 3 Trial - Stock Titan
Dermata Therapeutics Faces Nasdaq Delisting Notice By Investing.com - Investing.com Australia
Dermata Therapeutics Faces Nasdaq Delisting Notice - Investing.com
Dermata Therapeutics, Inc. SEC 10-K Report - TradingView
Major Catalyst Alert: Dermata's Phase 3 Acne Treatment Results Coming in Weeks - StockTitan
Stocks Rally as US Consumer Prices Cool - The Globe and Mail
Acne Market on Track for Major Expansion by 2032, According to DelveInsight | Clinuvel Pharma, Novan, Dermata Therapeutics, ioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies - Barchart
Acne Market on Track for Major Expansion by 2032, According - openPR
Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne - openPR
Tesla Stock is OversoldIs Now the Time to Be Brave? - The Globe and Mail
Geron (NASDAQ:GERN) versus Dermata Therapeutics (NASDAQ:DRMA) Head-To-Head Comparison - Defense World
Dermata Announces That Last Patient Completes Last Visit In Pivotal Xyngari Phase 3 Star-1 Clinical Trial For Acne - Marketscreener.com
Dermata Therapeutics announces last patient visit in Phase 3 acne trial - TipRanks
Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne - PR Newswire
Acne Market Predicted to See Upsurge Through 2032, Highlights - openPR
Papulopustular Rosacea Clinical and Non-Clinical Studies, Key - openPR
APO accepts Dermata’s patent application for DMT410 program for hyperhidrosis - MSN
Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - Benzinga
DRMADermata Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis - ACCESS Newswire
Dermata Therapeutics announces $2.55M private offering - MSN
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules - ACCESS Newswire
Crown Labs completes acquisition of Revance Therapeutics By Investing.com - Investing.com Nigeria
Crown Labs completes acquisition of Revance Therapeutics - Investing.com India
Dermata to Present on BioPub on January 31, 2025 - ACCESS Newswire
Dermata Unveils Game-Changing Skin Disease Treatment Progress: CEO Reveals What's Next - StockTitan
Acne Vulgaris Market Expected to rise, 2034 | Pelthos - openPR
Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment - ACCESS Newswire
Dermata Therapeutics Signs Clinical Trial Collaboration Agreement with Revance Therapeutics for Topical Treatment StudyDermata Therapeutics, Inc. (NASDAQ: DRMA) revealed in an 8-K filing that on January 17, 2025, the company entered into a Clinical T - Defense World
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024 - ACCESS Newswire
Dermata Therapeutics Announces Private Placement of $2.4 Million in Securities SAN DIEGO, CA – Dermata Therapeutics, Inc. (NASDAQ: DRMA) disclosed in a filing on January 21, 2025, that it has entered into a securities purchase agreement for a private - Defense World
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne - ACCESS Newswire
Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - ACCESS Newswire
Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering - ACCESS Newswire
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne - ACCESS Newswire
Finanzdaten der Dermata Therapeutics Inc-Aktie (DRMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.89%
0.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):